David Harlan to Hypoglycemic Agents
This is a "connection" page, showing publications David Harlan has written about Hypoglycemic Agents.
Connection Strength
1.196
-
Feigenbaum K, Brooks PG, Chamberlain CE, Cochran E, Adams-McLean A, Malek R, Harlan DM. The Clinical Center's blood glucose management service: a story in quality integrated care. Diabetes Educ. 2012 Mar-Apr; 38(2):194-206.
Score: 0.334
-
Rother KI, Spain LM, Wesley RA, Digon BJ, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009 Dec; 32(12):2251-7.
Score: 0.287
-
El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 01 28; 389(10067):369-380.
Score: 0.118
-
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670. Diabetes Care. 2014 Oct; 37(10):e219-20.
Score: 0.101
-
Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014; 37(3):666-70.
Score: 0.095
-
Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011 Apr; 13(4):457-60.
Score: 0.079
-
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9.
Score: 0.053
-
Naftanel MA, Harlan DM. Pancreatic islet transplantation. PLoS Med. 2004 Dec; 1(3):e58; quiz e75.
Score: 0.051
-
Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 2014 May; 63(5):1748-62.
Score: 0.024
-
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul; 33(7):1674-85.
Score: 0.019
-
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010 Jul-Aug; 60(4):207-21.
Score: 0.019
-
Perl S, Hirshberg B, Harlan DM, Tisdale JF. How much insulin is enough? A quantitative assessment of the transdifferentiaton potential of liver. Diabetologia. 2007 Mar; 50(3):690-2.
Score: 0.015